Articles published by ImmunityBio, Inc.

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

May 07, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

May 05, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

April 21, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

April 09, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

April 06, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

March 31, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

March 26, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

March 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

March 17, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

March 13, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

February 26, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

February 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

February 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

February 19, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

February 18, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

February 17, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

January 15, 2026

From ImmunityBio, Inc.

Via Business Wire

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

January 14, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

January 13, 2026

From ImmunityBio, Inc.

Via Business Wire

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

January 12, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

December 29, 2025

From ImmunityBio, Inc.

Via Business Wire

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

December 16, 2025

From ImmunityBio, Inc.

Via Business Wire

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

November 13, 2025

From ImmunityBio, Inc.

Via Business Wire

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

November 04, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

September 08, 2025

From ImmunityBio, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.